Medifron DBT Co. Ltd Asset Resilience Ratio
Medifron DBT Co. Ltd asset resilience ratio. Medifron DBT Co. Ltd (065650) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Medifron DBT Co. Ltd (065650) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Medifron DBT Co. Ltd (2014–2024)
Asset resilience ratio of Medifron DBT Co. Ltd from 2014 to 2024. This chart shows how Medifron DBT Co. Ltd's Asset Resilience Ratio has changed over time. Read debt load of Medifron DBT Co. Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Medifron DBT Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Medifron DBT Co. Ltd (065650) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩470.00 | 0.0% |
| Total Liquid Assets | ₩470.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Medifron DBT Co. Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Medifron DBT Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Medifron DBT Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Medifron DBT Co. Ltd Asset Resilience Ratio by Year (2014–2024)
Medifron DBT Co. Ltd asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for Medifron DBT Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.61% | ₩7.62 Billion ≈ $5.16 Million |
₩60.40 Billion ≈ $40.94 Million |
-10.69pp |
| 2023-12-31 | 23.30% | ₩13.00 Billion ≈ $8.81 Million |
₩55.79 Billion ≈ $37.81 Million |
-23.65pp |
| 2022-12-31 | 46.95% | ₩26.18 Billion ≈ $17.74 Million |
₩55.75 Billion ≈ $37.78 Million |
+27.36pp |
| 2021-12-31 | 19.59% | ₩9.62 Billion ≈ $6.52 Million |
₩49.10 Billion ≈ $33.27 Million |
-9.97pp |
| 2020-12-31 | 29.57% | ₩13.96 Billion ≈ $9.46 Million |
₩47.22 Billion ≈ $32.00 Million |
-21.61pp |
| 2019-12-31 | 51.17% | ₩9.96 Billion ≈ $6.75 Million |
₩19.46 Billion ≈ $13.19 Million |
-14.19pp |
| 2018-12-31 | 65.37% | ₩14.10 Billion ≈ $9.56 Million |
₩21.57 Billion ≈ $14.62 Million |
+8.58pp |
| 2017-12-31 | 56.78% | ₩14.90 Billion ≈ $10.10 Million |
₩26.24 Billion ≈ $17.78 Million |
+37.45pp |
| 2016-12-31 | 19.33% | ₩5.37 Billion ≈ $3.64 Million |
₩27.75 Billion ≈ $18.81 Million |
+9.60pp |
| 2015-12-31 | 9.73% | ₩3.00 Billion ≈ $2.03 Million |
₩30.84 Billion ≈ $20.90 Million |
+1.04pp |
| 2014-12-31 | 8.69% | ₩2.30 Billion ≈ $1.56 Million |
₩26.48 Billion ≈ $17.95 Million |
-- |
About Medifron DBT Co. Ltd
Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD… Read more